)
Edge31 Oct 2025
Rolls-Royce: Full Thrust Ahead
From century-old crafted perfection to pandemic shock and reset, Rolls-Royce's story is shaped by heritage, turbulence, and a disciplined climb back.
NeoGenomics (NEO) investor relations material
NeoGenomics Q3 2025 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q3 2025 earnings summary28 Oct, 2025
Executive summary
Q3 2025 revenue reached $188M, up 12% year-over-year, driven by record clinical volumes, 18% clinical revenue growth, and 24% NGS revenue growth, with NGS now comprising nearly one-third of clinical revenue.
Net loss increased to $27.1M, reflecting higher operating expenses and impairment charges, while adjusted EBITDA was $12.2M, marking the ninth consecutive positive quarter but down 9% year-over-year.
Pathline acquisition expanded presence in the Northeast, contributing to higher test volumes and improved turnaround times.
Major product launches included RaDaR ST MRD assay, supported by a favorable court ruling and MolDX approval, and PanTracer LBx, with strong initial interest.
Ongoing investments in R&D and business development target the $40B therapy selection and $30B MRD markets, with continued focus on community oncology and broadening hospital partnerships.
Financial highlights
Q3 2025 total revenue was $188M, up 12% year-over-year; clinical revenue grew 18%, and NGS revenue rose 24%, accounting for 33% of clinical revenue year-to-date.
Adjusted gross profit was $85.4M (up 7% year-over-year), with a gross margin of 43% and adjusted gross margin of 45.5%.
Adjusted EBITDA was $12.2M, down 8.5% year-over-year; net loss (GAAP) was $27.1M, or $(0.21) per share.
Operating expenses rose 12% to $107M, including $7.1M in impairment charges and higher compensation costs.
Cash and cash equivalents at quarter-end were $164M.
Outlook and guidance
Full-year 2025 revenue guidance reaffirmed at $720M–$726M (9–10% growth), with adjusted EBITDA of $41M–$44M and net loss expected between $108M–$116M.
Adjusted diluted EPS for 2025 projected at $0.08–$0.12; 2026 guidance to be provided with full-year results.
Growth drivers for 2026 include continued clinical and NGS momentum, new product launches, and Pathline integration.
Future capital deployment strategy?
Rationale for Trapelo/InVision divestitures?
Drivers for Q4 Adjusted EBITDA recovery?
RaDaR ST: New indications and timing?
Pharma business: Key internal growth drivers?
LIMS project: Tangible 2026 efficiency gains?
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Next NeoGenomics earnings date
Stephens Annual Investment Conference19 Nov, 2025
Next NeoGenomics earnings date
Stephens Annual Investment Conference19 Nov, 2025
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
NeoGenomics Inc provides cancer-focused genetic testing services, including clinical and research laboratory diagnostics. The company offers molecular, cytogenetic, and flow cytometry testing to pathologists, oncologists, and pharmaceutical companies. It supports precision medicine and oncology drug development. The company is headquartered in Fort Myers, Florida, and its shares are listed on the NASDAQ.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage